Swissmedic resumes Inspections
Swissmedic, the Swiss Agency for Therapeutic Products, has announced "to resume regular on-site inspections", provided that the "necessary protective measures can be complied with". A safe inspection procedure must be guaranteed for all those involved.
Before the GMP/GDP inspection, the company to be inspected must fill out a questionnaire. This questionnaire contains instructions and measures which should be observed during the inspection. The companies are asked to complete the questionnaire and to confirm the measures accordingly.
On site, the inspected company must then make appropriate arrangements, such as "meeting rooms with sufficient space, restricted number of participants, electronic resources" and wearing face masks if necessary.
Related GMP News
02.09.2026Deficiencies in Staffing, Monitoring and Aseptic Techniques – Warning Letter to a European Company
26.08.2026FDA Warning Letter: Inadequate Warehouse Controls and Lot Traceability
19.08.2026Poor Hygiene and Environmental Conditions - FDA Warning Letter
28.07.2026Pre-approval Inspections: FDA introduces New Guidance
22.07.2026Do you know about QPSHARE?



